CompletedNCT02046369
Lurasidone for Depression in Children and Teens Living With Bipolarity
About this title
Read the official source — NCT02046369Researchers compared Lurasidone and placebo, tracking side effects to assess safety in children with bipolarity type I during a depressive episode.
Medication studyAges 10–17Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Lurasidone and placebo, tracking side effects to assess safety in children with bipolarity type I during a depressive episode.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Dothan and 65 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 350
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Bulgaria, ...
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT02046369
- Official title
Show the full official title
A Randomized, 6-Week, Double-blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Bipolar I Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Dothan, United States · Culver City, United States · Hartford, United States
60 more locations
- Gainesville, United States
- Orlando, United States
- Atlanta, United States
- Smyrna, United States
- Libertyville, United States
- Overland Park, United States
- Lake Charles, United States
- Baltimore, United States
- Bloomfield Hills, United States
- Saint Charles, United States
- Neptune City, United States
- Glen Oaks, United States
- Mount Kisco, United States
- Rochester, United States
- Staten Island, United States
- Cincinnati, United States
- Cleveland, United States
- Oklahoma City, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- The Woodlands, United States
- Clinton, United States
- Orem, United States
- Charlottesville, United States
- Petersburg, United States
- Bothell, United States
- Rousse, Bulgaria
- Targovishte, Bulgaria
- Varna, Bulgaria
- Barranquilla, Colombia
- Bogotá, Colombia
- Nice, France
- Nantes, France
- Budapest, Hungary
- Gyula, Hungary
- Monterrey, Mexico
- Culiacán, Mexico
- Durango, Mexico
- San Luis Potosí City, Mexico
- Iloilo City, Philippines
- Mandaluyong, Philippines
- Quezon City, Philippines
- Kobierzyce, Poland
- Torun, Poland
- Warsaw, Poland
- San Juan, Puerto Rico
- Jeonju, South Korea
- Gwangju, South Korea
- Incheon, South Korea
- Seongnam-si, South Korea
- Seoul, South Korea
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Ternopil, Ukraine
- Vinnytsia, Ukraine
Questions about this study
What did researchers investigate?
Researchers compared Lurasidone and placebo, tracking side effects to assess safety in children with bipolarity type I during a depressive episode.
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone and Placebo.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.
